Nintedanib in advanced NSCLC: management of adverse events

Nintedanib plus docetaxel is approved in the EU for the treatment of patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma histology after first-line chemotherapy. Nintedanib in combination with docetaxel has a manageable safety profile in adenocarcinoma NSCLC patie...

Descripción completa

Detalles Bibliográficos
Autor principal: Lemmens, Liesbeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322586/
https://www.ncbi.nlm.nih.gov/pubmed/30643547
http://dx.doi.org/10.2217/lmt.15.33

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322586/
https://www.ncbi.nlm.nih.gov/pubmed/30643547
http://dx.doi.org/10.2217/lmt.15.33

Ejemplares similares